Moreover, the treatment with benzodiazepines is common practice in the absence of class I or II level of evidence. Here we assessed the role of benzodiazepines in the conservative management of acute lumbar disc prolapse.
Is there a role for benzodiazepines in the management of lumbar disc prolapse with acute sciatica?
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Introduction
Lower back pain is one of the commonest diagnoses associated with sick leave and chronic disability. Most presumed standards of care have not been confirmed to effective in appropriate clinical trials (8) (9) (10) 26) . A 2003 Cochrane review concluded that "muscle relaxants are effective in the management of non-specific low back pain, but the adverse effects require that they be used with caution" (27) . Approximately 5% of the patients with lower back pain suffer from lumbar disc prolapses verified by neuroimaging (15) . The conservative management of clinical symptoms and signs associated with lumbar disc prolapse includes rest, various strategies of physiotherapy and various medications, notably non-steroidal anti-inflammatory agents or low-to-medium potency opioids, and muscle relaxants, mostly benzodiazepines (7, 29) . Because of their sedative effects and a potential for addiction, both opioids and benzodiazepines should only be used where they are clearly effective and indicated.
The first randomized trial that we identified did not demonstrate a superior outcome for patients with unspecific acute lower back pain treated with diazepam as opposed to placebo, but that study was performed more than 40 years ago, prior to the availability of computed tomography (CT) and magnetic resonance imaging (MRI) (16) . A recent review (26) concluded that randomized trials had reported little efficacy of diazepam in acute unspecific lower back pain (23) and either no (5) or only minor benefits from benzodiazepines in patients with chronic unspecific lower back pain (4, 25) . Only 20% of the conservatively treated patients received muscle relaxants in the US (29) . This figure is probably higher in Europe.
Although there are almost no prospective studies on the impact of various approaches of physiotherapy on the symptoms and course of lumbar disc prolapse, physiotherapy is commonly prescribed in this patient population. We have confirmed active mechanical physiotherapy based on the pathophysiological concepts of centralization versus peripheralization of referred pain (12, 19, 21) to be feasible and acceptable to many patients with lumbar disc prolapse (6) . Peripheralization and centralization refer to changes in the projected area of radicular pain associated with lumbar disc prolapse. In a previous prospective phase II trial, centralization was found to be predictive of a favourable outcome in patients with lumbar disc prolapse (6).
Patients with low back pain and acute sciatica from lumbar disc prolapse usually exhibit an enhanced tone of the lumbar extensor muscles, a reduction of the physiological lumbar lordosis and a lateral shift of the vertebral column (3, 20, 28) . The increased tone of the extensor muscles may not be a pathological response pattern, but may actually serve a protective function to prevent flexion of the spine and thus an increase of the prolapse. Some doubts therefore remain regarding the use of muscle relaxants in the acute phase of conservative treatment of this condition. The present trial sought to evaluate whether the outcome of conservative treatment of lumber disc prolapse with mechanical physiotherapy using repeated spinal movements in a preferred direction and analgesics, but without benzodiazepines, is equivalent to the same treatment plus benzodiazepines.
Methods
Patients
This prospective, randomized, placebo-controlled, double-blind trial (ClinicalTrials.gov ID NCT00533286) was approved by the Ethics Committee of University of Tübingen Medical School (53/2001). All participating patients gave written informed consent. The trial included patients who fulfilled the following inclusion criteria: age between 18 and 75 years, sciatica without or with neurological deficit attributable to lumbar disc prolapse, CT or MRI confirmation of lumbar disc prolapse, pain centralization within the first physical therapy session and informed consent. The length of the pain history was not specified in the inclusion criteria. Patients could not be enrolled if they had bladder or bowel disturbance or acute (< 24 h) development of paresis grade 1 or plegia (14) because these patients were considered candidates for surgery. Further, patients could not have had taken benzodiazepines for more than 2 weeks, any history of benzodiazepine intolerance, prior surgery for disc prolapse, or prior trauma to the vertebral column.
Study design
The patients were randomized after informed consent in the order of consenting using a computerized randomization list at the Medical Biometry Unit to receive placebo (2 tablets daily, arm A) or diazepam (2 x 5 mg) (arm B). This list contained numbers reflecting treatment A or B. This numbers were used to identify the bottles with separately manufactured study medication which matched placebo and diazepam in size, shape and color. This approach prevented the consenting physician from knowing the result of the randomization process by estimating from the preceeding patient. The bottle with study medication was stored at the ward and the medication was given to the patient on a daily basis. Patients, physiotherapists (DB, EM, SB) and the clinical neurologists (WW, MW) were blinded to treatment arm allocation. The medication was adjusted and gradually tapered from day 5 on by the treating physicians in cooperation with the principle investigator (MW). The guidelines for tapering followed the general practice of our physicians to reduce diazepam doses depending on symptom reduction reported by the patient. The use of other muscle relaxants was not permitted. The treating physiotherapists, physicians and patients remained blinded throughout the study and the reports from the hospital did not disclose the study arm that the patient was allocated to. Mechanical physiotherapy was administered as extensively described (6) and diclofenac was used as the basic analgesic and anti-inflammatory agent.
Its dose was adapted according to patients` needs and as deemed necessary by the treating physicians. Further analgesics were allowed according to the preference of the treating physicians. The extent of the lumbar disc prolapses on CT or MRI was assessed as previously described (6) .
Endpoints and follow-up
The patients were documented at the day of study entry (day 1) and then at days 3, 5, 7, 9 and at the day of discharge from hospital. Follow-up examinations were scheduled at 6 weeks and at one year after discharge. The endpoints were planned to be assessed at day 7 compared with day 1. The following parameters were measured or documented (12, 24) : centralization, impairment (disability scale), pain on a visual analog scale, duration of pain within 24 h, straight leg raise in angular degrees, quality and extension of sensory loss, muscle strength, and walking distance and mobility (finger floor distance). The primary endpoint was defined as the extent of reduction (centralization) of referred pain in percent at day 7 compared with day 1. The distance from the affected vertebral segment at the lower back to the area of most distal pain projection was measured in cm. Increases in pain projection were to be calculated as 0% reduction. Such patients would be considered candidates for surgery. In fact, only one patient of group A developed such a peripheralization of pain projection of 1 cm until day 7. Therefore, counting negative values not as 0% reduction, but actually as negative values might have been more correct theoretically, but did not alter the study results here (data not shown). Secondary endpoints were as follows: duration of inability to work after discharge measured in days as determined 7 by the local treating physicians, duration of stay in hospital, reduction of scores on the Roland-Morris disability scale on day 7 compared with day 1, number of patients with: pain reduction on the visual analog scale of 50% or more on day 7 compared with day 1; increase in the straight leg raise by 50% or more; reduction of time (h) with pain by 50% or more; changes of sensory loss; improved muscle strength by at least one grade; improvement of finger floor distance; walking distance at day 7; consumption of study medication and of diclofenac per D1-D7 (mg); request for further anagesics, and inability to work at 4 weeks after discharge.
Statistics
Based on the sample size consideration 60 patients were included into the study. This was calculated to be sufficient for proving the equivalence of the two therapies regarding the centralization of the referred pain between study day 1 and 7 in percent with an equivalence tolerance delta of 20% (alpha=5%, beta=10%). A clean file of the data was submitted to the Institute for Medical Biometry at the University of Tübingen for the final analyses. Data analyses were performed by C.E. with the statistical analysis software SAS (version 9.1.3, SAS Institute Inc, Cary, NC, USA) based on the intention-to-treat population from which none of the randomized patients had to be excluded. All endpoints were measured as changes between study day 1 and 7 if not otherwise mentioned. Missing data were not replaced. The primary endpoint was tested using the Mann-Whitney test of equivalence (30) because the data were not normally distributed. The 95% confidence interval for the difference in the primary endpoint between placebo and diazepam was calculated according to Altman and colleagues (2) . The normally distributed endpoint improvement of finger floor distance was analyzed using Student's t-test. The U-Test was used for non-normally distributed continuous endpoints (duration of inability to work, reduction of disability scores, walking distance at day 7, consumption of diclofenac and study medication, absolute duration of stay in hospital and improvement of finger floor distance). The secondary endpoints reduction on the visual analog scale of at least 50%, increase of the straight leg raise of at least 50%, reduction of Table, chiefly because they did not meet the inclusion criteria (Fig. 1) . The study population consisted of 26 females and 34 males. Patient characteristics are summarized in Table 1 . Tables 2 and 3 . The primary endpoint defined as the median centralization of referred pain at day 7 showed equivalence within the predefined tolerance of equivalence of 20% between placebo (60%) and diazepam (50%) (p<0.05).
Specifically, this test sought to demonstrate that the median difference in favor of diazepam, if any, is truly less than 20%. The observed difference was 10% in favor of placebo, and this was indeed statistically different from a null hypothesis of 20% in favor of diazepam. The result does not provide evidence for a complete absence of a difference, but the 95% confidence interval for the differences in centralization in referred pain between placebo and diazepam was -15% to 24%. This result is not fully congruent with the result of the equivalence test, but if there may be a difference of more than 20%, it is in favor of placebo, which also confirmes the primary hypothesis. Accordingly, we thus confirmed the primary hypothesis that the conservative treatment used here without diazepam support is not inferior to the same treatment with diazepam support. Moreover, the median duration of the stay in hospital was shorter in the placebo arm (8 vs. 10 days, p=0.008), and the probability of pain reduction on the visual analog scale by more than 50% was twice as high in placebo patients (p=0.0015).
Most other secondary endpoints appeared to favor the placebo arm, too, although the differences were not significant. This includes the median duration of inability to work after discharge (15 vs. 26 days, p=0.73); the median reduction of scores on the Roland-Morris disability scale on day 7 compared with day 1 (5 points reduction vs. 3 points, p=0.67); the number of patients with reduction of sensory loss (63% vs. 50%, p=0.63); the median walking distance at day 7 (1000 meters in both groups because 25 placebo patients and 19 diazepam patients reached 1000 m, but different ranges, p=0.07); the median consumption of diclofenac per D1-D7 (750 mg in both groups but different ranges, p=0.78. Additionally patients in the placebo group showed a 1.25-fold higher chance of a reduction of time (h) with pain by 50% or more at day 7 compared with day 1 (p=0.26) and an improvement of muscle strength by at least one grade (p=0.54) whereas patients in the diazepam group showed a 1.3-fold risk of not being able to work at 4 weeks after discharge (p=0.43) and the request for further analgesics in addition to diclofenac was 1.3-fold higher (p=0.36) ( Table 4 ).
In contrast, there was a 1.2-fold higher chance for an increase in the straight leg raise by 50% or more in the diazepam arm (p=0.79) and the mean improvement of the finger floor distance was higher in this group (6.2 cm vs 5.0 cm, p=0.75).
Six placebo patients and 7 diazepam patients had surgery within 6 weeks of study entry.
Overall seven placebo patients and 8 diazepam patients had surgery within one year of study 
Discussion
It is a common belief that muscle tension causes lower back pain. Accordingly, various measures assumed to reduce pathologically enhanced muscle tension including muscle relaxants, massages and physical applications have become part of the general therapeutic repertoire for patients with lower back pain (18) and specifically for patients with lumbar disc prolapse. The therapeutic efficacy of these measures has remained obscure.
Flexion of the vertebral column, the major contributor to lumbar disc stress, causes an anterior approximation of the vertebral bodies, a mechanical dislocation of the nucleus pulposus backwards and ultimately a lumbar disc prolapse associated with sciatica and neurological deficits attributable to root compression (1, 13) . Experimental studies have indicated that porcine lumbar discs respond to damage induced by electrical stimulation with an increased tone of the erector trunci muscles (17) . Accordingly, we hypothesized that the increased muscle tone in human patients with lumbar disc prolapses may serve the aim to prevent further flexion of the spine and further flexion-associated disc damage.
Our current standard approach of physiotherapy for these patients (6) aims at preventing a further dislocation of nucleus pulposus material and instead relieving the posterior annulus fibrosis from mechanical pressure. The concurrent use of benzodiazepines such as diazepam would not only weaken the natural protective response of increased muscle tone in the erector trunci muscle, but would also counteract this treatment strategy.
The results of the present prospective randomized trial questions the value of prescribing benzodiazepines in the first days of conservative treatment of sciatica associated with lumbar disc prolapse. We studied a well-characterized and deliberately enriched patient population not just suffering from unspecific lower back pain, but from sciatica attributable clinically to a defined lesion documented by neuroimaging. We excluded patients where we judged immediate surgery to be necessary, this is, patients with bladder or bowel disturbance or acute (< 24 h) development of paresis grade 1 or plegia (14) . The patients enrolled in our trial were in principle all candidates for elective surgery because they had neurological symptoms or signs or both attributable to a radiologically verified lesion. On the other hand, we (6) and others have made the experience that many of these patients can be managed with conservative treatment. In that regard, the rate of surgery of 13 of 60 patients within 6 weeks of study entry was not unexpected.
The patient characteristics in both study arms of the present study were well-balanced for all clinical parameters except for the higher frequency of larger disc prolapses in the placebo group (Table 1) . Although one might hypothesize that this may have favored the diazepam group, there is indeed no evidence that the size of prolapses predicts outcome (22). The primary endpoint defined as centralization of referred pain at day 7 showed equivalence between placebo and diazepam at the dosing schedule used here within the defined equivalence tolerance. In retrospect, it might have been preferable to assess back and leg pain separately as outcome measures (11) . Yet, the diazepam group did also not show superiority in any of several secondary endpoints evaluated at day 7 after the start of treatment (Tables 2 and 3 ). Moreover, the median duration of the stay in hospital was shorter in the placebo arm. We are aware that this endpoint is of minor significance since the patient population studied here is managed as out-patients in many countries throughout the world.
Further, the probability of pain reduction on a visual analog scale by more than 50% was twice as high in placebo patients.
Admittedly, this study has some inherent weaknesses: we did not prove that muscle relaxation was truly achieved by the doses of diazepam used here and we cannot rule out that diazepam was underdosed or that sedative effects interfered with a possible effect that could be derived from the pharmacological effect of muscle relaxation. Of note, the follow-up data at one year do not suggest a longterm adverse effect of benzodiazepines either.
Anyhow, our trial results allow to conclude that benzodiazepines should no longer be considered standard of care for the acute conservative treatment of sciatica associated with lumbar disc prolapse. Chronic pain (more than 90 days) 2 3
Preexposure to analgesics (mainly diclofenac) within last 
